The Women's Health Initiative (WHI) is a long-term national health study that focuses on strategies for preventing heart disease, breast cancer, colorectal cancer, and osteoporotic fractures in postmenopausal women. The study includes data from 161,808 women aged 50-79. Datasets include information on demographics, diet, medical and physical measurements, medical history, outcomes (both adjudicated...

The Nurses' Health Studies (NHS) are long-running, questionnaire-based studies on women's health. The study was started in 1976 and expanded in 1989 and includes data from 238,000 female, nurse-participants. The study focuses on cancer, cardiovascular disease and risk factors for chronic health issues in women. The dataset includes both survey data and biospecimens.

The Surveillance, Epidemiology, and End Results (SEER) Program at the National Cancer Institute (NCI) is the authoritative source of information on cancer incidence and survival in the United States. SEER collects data on cancer incidence and population data associated by age, sex, race, year of diagnosis, and geographic area. Sub-directories break the dataset in cancer sites, including breast, colon...

The Clinical Proteomic Tumor Analysis Consortium (CPTAC) analyzes cancer biospecimens by mass spectrometry, characterizing and quantifying their constituent proteins, or proteome. Proteomic analysis for each CPTAC study is carried out independently by Proteomic Characterization Centers (PCCs) using a variety of protein fractionation techniques, instrumentation, and workflows. Mass spectrometry and...

Health Information National Trends Survey (HINTS) collects nationally representative data about the American public's use of cancer-related information. The survey collects information about cancer communication, cancer perceptions and knowledge, demographics, food and medical products information, health communication, health services, health status, internet use, medical research and medical records,...

The Cancer Genome Atlas (TCGA), a landmark cancer genomics program, molecularly characterized over 20,000 primary cancer and matched normal samples spanning 33 cancer types. This joint effort between NCI and the National Human Genome Research Institute began in 2006, bringing together researchers from diverse disciplines and multiple institutions. Over the next dozen years, TCGA generated over 2.5...

The mutations that cause cancer cells to grow also confer specific vulnerabilities that normal cells lack. Some of these acquired alterations represent compelling therapeutic targets. The challenge is that, for the overwhelming majority of cancers, we do not fully understand the relationship between the genetic alterations of cancer and the dependencies they cause. To solve this problem, we are creating...

AACR Project GENIE is a publicly accessible international cancer registry of real-world data assembled through data sharing between 19 of the leading cancer centers in the world. Through the efforts of strategic partners Sage Bionetworks and cBioPortal, the registry aggregates, harmonizes, and links clinical-grade, next-generation cancer genomic sequencing data with clinical outcomes obtained during...

Here we investigated different cell populations within ovarian cancer using single-cell RNA seq: fourteen samples from nine patients with differing grades (high grade, low grade and benign) as well as different origin sites (primary and metastatic tumor site, ovarian in origin and fallopian in origin).

The purpose of this microarray is to identify genes that may be differentially expressed in M1 or M2 macrophages after treatment with CNI-1493. CNI-1493 is a known inhibitor of M1 macrophages but details of its molecular mechanism are unknown. The effect of CNI-1493 on M2 macrophages has yet to be explored, but we hypothesize that CNI-1493 treatment will attenuate pro-tumor properties of M2 macrophages....